Mumbai (Maharashtra) [India], January 17: As India grapples with a diabetes epidemic, Fitterfly, a leading ISO-13485 certified digital therapeutics company with clinically-proven programs, releases its comprehensive report, Reimagining Diabetes Care 2024 . This study showcases the data from the Fitterfly Diabetes prime program across 2023 and the critical role digital therapies now play in empowering people to effectively manage diabetes.
Mumbai (Maharashtra) [India], March 7 (ANI/PRNewswire): Fitterfly, a leading Indian health-tech company, working in the area of diabetes & metabolic health, recently showcased data from its Digital Therapeutics Technology platform at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023) in Berlin, Germany. Fitterfly is the one of the few Indian healthcare companies to have received this opportunity in the last 16 years, thereby putting the company's efforts in the area of DTx on the world map. Besides research studies, this year Fitterfly was the only Indian Digital Therapeutics company invited to exhibit at the Tech Fair Expo in the innovation segment. The purpose of the ATTD meeting is to highlight innovative technologies and treatments in diabetes management. It brings together developers of new technologies with diabetes professionals and caretakers, researchers, industries, startup companies, investors, reimbursement authorities
Best Media Info: The rebranding aims to augment Fitterfly’s new and bold vision of being the first line of therapy for metabolic health| Marketing News